Диссертация (1139475), страница 33
Текст из файла (страница 33)
19, 1109–1114(2015).268. Akshata J. S. & Chakrabarthy, A. Management of multidrug resistanttuberculosis (MDR-TB) - Monitoring is the key to successfuloutcome. J ChestDis Tuberc. 65, 447–450 (2016).269. Alangaden, G.J., Kreiswirth, B.N., Aouad, A., Khetarpal, M., Igno, F.R.,Moghazeh, S.L., Manavathu, E.K., Lerner, S.A.
Mechanism of resistance toamikacin and kanamycin in Mycobacterium tuberculosis // Antimicrob. AgentsChemother. - 1998. – Vol 42. - P.1295 - 1297.270. Alcaide F., Pfyffer G. E., Telenti A. Role of embB in natural and acquiredresistance to ethambutol in mycobacteria // Antimicrobial Agents andChemotherapy. – 1997. – Vol. 41. № 10. – P. 2270 – 2273.271. Alexander G.R. and Biccard B. A retrospective review comparing treatmentoutcomes of adjuvant lung resection for drug-resistant tuberculosis in patientswith and without human immunodeficiency virus co-infection European Journalof Cardio-Thoracic Surgery 2016; 49: 823–828.272. Almeida Da Silva PE, Palomino JC.Molecular basis and mechanisms ofdrug resistance in Mycobacterium tuberculosis: classical and new drugs. JAntimicrob Chemother. 2011, Jul;66(7), pp.
1417-30.228273. AmericanThoracicSociety/CentersforDiseaseControl,Prevention/Infectious Disease Society of America. Treatment of tuberculosis. //Am J Respir Crit Care Med 2003; 167: 603–62.274. Andre E. et al. Consensus numbering system for the rifampicin resistanceassociated rpoB gene mutations in pathogenic mycobacteria // ClinicalMicrobiology and Infection. – 2017. –Vol.
23. - № 3. – P. 167-172.275. Andries, K., Verhasselt, P., Guillemont, J., et al. A diarylquinoline drugactive on the ATP synthase of Mycobacterium tuberculosis // Science. – 2005. –Vol. 307. – P. 223 - 227.276. Antimicrobial Resistance: Tackling a crisis for the health and wealth ofnations. The Review on Antimicrobial Resistance Chaired by Jim O’NeillDecember2014. https://amr-review.org.277. Avong Y. K. Doing no harm? Adverse events in a nationwide cohort ofpatients with multidrug resistant tuberculosis in Nigeria / Y.K.
Avong, P.Isaakidis, S. G. Hinderaker, R. Van den Bergh, E. Ali, B.O. Obembe, E. Ekong,C. Adebamowo, N. Ndembi, J. Okuma // PLoS ONE. – 2015. – Vol. 10. – №3.– e0120161 [Электронный ресурс]. – Режим доступа: doi:10.1371/journal.pone.0120161.278. Barker W. Thoracoplasty // Chest Surg. Clin.
N. Am. – 1994. – Vol. 4. - №3.– P. 593-615.279. Bastian I., Colebunders R. Treatment and prevention of multidrug-resistanttuberculosis // Drugs. - 1999. - Vol. 58. - №4. - P.633-661.280. Bazira J. Use of the GenoType®MTBDRplus assay to assess drug resistanceof Mycobacterium tuberculosis isolates from patients in rural Uganda / J.
Bazira,B.B. Asiimwe, M.L. Joloba, F. Bwanga, M.I. Matee // BMC Clinical Pathology.– 2010. – Vol. 10 (5). – P. 1472-1476.281. Bendayan D., Hendler, A., Polansky, V. & Weinberger, M. Outcome ofhospitalized MDR-TB patients: Israel 2000–2005. J ClinMicrobiol. 30, 375–379 (2011).229282. Benson W.M., Stefko P.L., Roe M.D. // Am. Rev. Tuberc. – 1952. – Vol. 65.– P. 376-391.283. Bernshtein J., Lott W.A., Steinberg B.A., Yale H.L.
// Am. Rev. Tuberc. –1952. – Vol. 65. – P. 357-364.284. Bhushan B. Profile of adverse drug reactions in drug resistant tuberculosisfrom Punjab / B. Bhushan, R. Chander, N.C. Kajal, V. Ranga, A. Gupta, H.Bharti // Indian J Tuberc. – 2014. – Vol. 61 – №4. – P. 318–24.285. Bickford B., Ronald F. A critical review of the results of lung resection forpulmonary tuberculosis // Thorax.
– 1957. – Vol. 2. – Р. 2.286. Biuković Goran, Basak Sandip et al. Variations of Subunit ε of theMycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model forMechanism of Action of the Tuberculosis Drug TMC207 // AntimicrobialAgents and Chemotherapy. - 2012. - Vol. 57. - № 1. – Р. 168-176.287.
Blakemore R. Evaluation of the analytical performance of the XpertMTB/RIF Assay / R. Blakemore, E. Story, D. Helb, J. Kop, P. Banada et al. // J.Clin. Microbiol. – 2010. – Vol. 48 (7). – P. 2495–2501.288. Bloss E. Adverse events related to multidrug-resistant tuberculosistreatment, Latvia, 2000–2004 / E. Bloss, L. Kuksa, T.H. Holtz, V.
Riekstina, V.Skripconoka, S. Kammerer // Int J Tub Lung Dis. – 2010. – №14. – P. 275–281.289. Branscheid D., Albrecht C.M., Diemel K.D. Surgical therapy of pulmonarytuberculosis // Internist (Berl). – 2003. - Vol. 44. - №11. – Р. 1406-1412.290. Brossier F. et al. Comparative study of enzymatic activities of new KatGmutants from low- and high-level isoniazid-resistant clinical isolates ofMycobacterium tuberculosis // Tuberculosis.
– 2016. - Vol.100. - P. 15 - 24.291. Brossier F. Detection by GenoType MTBDRsl test of complex mechanismsof resistance to second-line drugs and ethambutol in multidrug-resistantMycobacterium tuberculosis complex isolates / F. Brossier, N. Veziris, A.Aubry, V. Jarlier, W. Sougakoff // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5.– P. 1683-1689.230292.
Brunello F. Reliability of the MB/BacT system for testing susceptibility ofMycobacterium tuberculosis complex isolates to antituberculosis drags / F.Brunello, R. Fontana // J. Clin. Microbiol. – 2000. – Vol. 38. – P. 872-873.293. Brust J. C. M., Gandhi, N. R., Carrara, H., Osburn, G. & Padayatchi, N. Hightreatment failure and default rates for patients withmultidrug-resistanttuberculosis in KwaZulu-Natal, South Africa, 2000–2003. J Tuberc. 14, 413–419 (2010).294. Casali N., Nikolayevskyy V., Balabanova Y.
et al. Evolution andtransmission of drug resistant tuberculosis in a Russian population // Nat.Genet.- 2014. – Vol. 46. – P. 279.295. CDC. Epidemiologic notes and reports nosocomial transmission ofmultidrugresistant tuberculosis to health-care workers and HIV-infectedpatients in an urban hospital - Florida // MMWR. Morb. Mortal. Wkly. Rep. –1990. – N. 39. – P. 718-722.296. CDC. Epidemiologic notes and reports nosocomial transmission ofmultidrugresistant tuberculosis among HIV-infected persons - Florida and NewYork // MMWR. Morb. Mortal.
Wkly. Rep. – 1991. – N. 40. – P. 585-591.297. CDC. Evaluation of a directly observed therapy short-course strategy fortreating tuberculosis in Orel oblast, Russian Federation, 1999-2000 // Morb.Mortal. Wkly. Rep. – 2001. – N. 50. – P. 204-206.298. Cegielski J. P. et al. Multidrug-Resistant Tuberculosis Treatment Outcomes inRelation to Treatment and Initial Versus AcquiredSecond-Line DrugResistance. Clin Infect Dis. 62, 418–430 (2016).299.
Central Intelligence Agency. The global infectious disease threat and itsimplicationsfortheUnitedStates.1999.www.odci.Gov/cia/publications/nie/report/nie99&17d.html.300. Champoux James J.DNA Topoisomerases: Structure, Function, andMechanism // Annual Review of Biochemistry. – 2001. - Vol.
70. – P. 369-413.301. Chan E.D. Current medical treatment for tuberculosis / E.D. Chan, M.D.Iseman // BMJ. – 30 Nov 2002. –Vol. 525. –P.1282-1286.231302. Charles M. et al. Treatment outcomes for patients with multidrug-resistanttuberculosis in post-earthquake Port-au-Prince, Haiti.J Trop Med. 91, 715–721(2014).303. Chiang C.Y., Yu M.C., Bai K.J., Suo J., Lin T.P., Lee Y.C. Pulmonaryresection in the treatment of patients with pulmonary multidrug-resistanttuberculosis in Taiwan // Int. J. Tuberc. Lung Dis. – 2001. – Vol. 5. - №3. – Р.272-277.304. Chung-Delgado K., Revilla-Montag A., Guillen-Bravo S.
& Bernabe-Ortiz A.Weight variation over time and its relevance amongmultidrug-resistanttuberculosis patients. J Infect Dis. 23, 20–24 (2014).305. Cohn M.L. Combined drug treatment of tuberculosis, I: Prevention ofemergence of mutant populations of tubercle bacilli resistant to bothstreptomycin and isoniazid in vitro / M.L. Cohn, G. Middlebrook, W. Jr.Russell // J. Clin. Invest. – 1959. – N. 38. – Р. 1349-1355.306. Cox H.
S. et al. Multidrug-resistant tuberculosis treatment outcomes inKarakalpakstan, Uzbekistan: treatment complexity andXDR-TB amongtreatmentfailures.PLoSONEElectronResour.2,e1126,https://doi.org/10.1371/journal.pone.0001126 (2007).307. Crofton J., Mitchinson D.A. Streptomycin resistance in pulmonarytuberculosis // Br. Med. J. – 1948. – Vol. 2. – P. 1009 - 15.308. Damasceno G. S. Adverse reactions to antituberculosis drugs inManguinhos, Rio de Janeiro, Brazil / G. S.
Damasceno, L. Guaraldo, E. M.Engstrom, M. M. T. Filha, R. S. Santos, A. G. G. Vasconcelos, S. Rozenfeld //Clinics. – 2013. – Vol. 68. – №3. – Р.329–337.309. Deoghare S. Bedaquiline: a new drug approved for treatment of multidrugresistant tuberculosis // Indian J Pharmacol. - 2013. – Vol. 45. - № 5. – P. 536537.310. Dheda K. et al. Early treatment outcomes and HIV status of patients withextensively drug-resistant tuberculosis in South Africa: aretrospective cohortstudy.
Lancet. 375, 1798–1807 (2010).232311. Dillon N.A., Peterson N.D., Rosen B.C., Baughn A.D., Pantothenate andpantetheine antagonize the antitubercular activity of pyrazinamide //Antimicrob. Agents Chemother. - 2014. – Vol. 58. – P. 7258 - 7263.312. Dolgusev O. et al. Pattern of primary tuberculosis drug resistance andassociated treatment outcomes in Transnistria, Moldova.Public Health Action.4, S64–S66 (2014).313. Domagk G, Behnisch R, Schmidt HS et al.
Über eine neue gegenTuberkelbazillen in vitro wirksame Verbindungsklasse. Naturwissenschaften1946; 33: 315.314. Domagk J., Offe H.A., Seifken W. // Dtch. Med. Wschr. – 1952. – Bd 77. – S.573-578.315. Dravniece G, Cain KP, Holtz TH, Riekstina V, Leimane V, Zaleskis R.Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis// Eur. Respir. J. - 2009. – Vol. 34.
- P. 180–83.316. Drobniewski F.,HutchinsonD.C.S.Multiple-drug-resfstanttuberculosis // Baillieres Clin. Infect. Dis. - 1999. - Vol. 5. - № 2. - P. 243-268.317. Drobniewski F., Eltringham I., Graham C. et al. A national study ofclinical and laboratory factors affecting the survival of patients with multipledrug resistant tuberculosis in the UK // Thorax. - 2002. - Vol. 57. - № 9. - P.810-816.318. Drug resistance of microorganisms. Robert J. Schnitzer, Emanuel Grunberg.New York, Acad.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
